
FTH Stock Forecast & Price Target
FTH Analyst Ratings
Bulls say
Faeth Therapeutics is a company with a promising pipeline of drugs, including PIKTOR, which has shown positive results in clinical trials and has potential for approval. The recent acquisition and partnership with SenseiBiotherapeutics provides further resources and expertise for future development and expansion. While competition and challenges may exist in the market, the development of interval dosing and potential for combination therapy provide opportunities for growth and success in treating endometrial and breast cancer.
Bears say
Faeth Therapeutics is a clinical-stage biotechnology company with a potential treatment, PIKTOR, for ER+/HER2- breast cancer and endometrial cancer. While its drug has shown promise in clinical trials, there are several other competitors with similar agents, raising concerns about market saturation. Additionally, the company was recently acquired, which may indicate a lack of confidence in its ability to reach success on its own. There is also a lack of data on long-term efficacy and potential side effects, making it difficult to fully evaluate the potential of the drug and the company's overall outlook.
This aggregate rating is based on analysts' research of Sensei Biotherapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
FTH Analyst Forecast & Price Prediction
Start investing in FTH
Order type
Buy in
Order amount
Est. shares
0 shares